Fredag 9 Maj | 19:16:49 Europe / Stockholm

Kalender

Est. tid*
2025-10-30 07:40 Kvartalsrapport 2025-Q3
2025-08-15 07:40 Kvartalsrapport 2025-Q2
2025-06-04 N/A X-dag halvårsutdelning VISTN 1.25
2025-05-22 N/A Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-06 - X-dag halvårsutdelning VISTN 0.5
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-05 - X-dag halvårsutdelning VISTN 0.5
2024-05-23 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2024-01-23 - X-dag ordinarie utdelning VISTN 0.75 NOK
2023-10-25 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-23 - X-dag ordinarie utdelning VISTN 0.00 NOK
2023-05-22 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-24 - X-dag ordinarie utdelning VISTN 0.00 NOK
2022-05-19 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning VISTN 0.50 NOK
2021-05-20 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-06-24 - Extra Bolagsstämma 2020
2020-05-20 - X-dag ordinarie utdelning VISTN 1.00 NOK
2020-05-19 - Årsstämma
2020-04-23 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning VISTN 0.00 NOK
2019-05-22 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-19 - Bokslutskommuniké 2018
2018-10-25 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning VISTN 1.00 NOK
2018-05-08 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-03 - X-dag bonusutdelning VISTN 7
2017-11-02 - Extra Bolagsstämma 2017
2017-10-27 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning VISTN 1.00 NOK
2017-05-24 - Årsstämma
2017-04-26 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-10-31 - Kvartalsrapport 2016-Q3
2016-08-30 - Kvartalsrapport 2016-Q2
2016-05-25 - X-dag ordinarie utdelning VISTN 0.60 NOK
2016-05-24 - Årsstämma
2016-04-28 - Kvartalsrapport 2016-Q1
2016-02-23 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriLäkemedel & Handel
Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Idag innehas verksamhet på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades under 2015 och har sitt huvudkontor i Oslo.
2022-04-27 07:45:00

Oslo, Norway, 27th of April 2022

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter 2022

Revenue in first quarter ended at MNOK 33 compared to MNOK 71 in Q1 2021. Decrease in revenue for the quarter driven by less volume available for sale due to the planned Metformin Expansion Project (MEP) installation.

First quarter EBITDA ended at negative MNOK 18 (Q1’21: MNOK 15). EBITDA unfavorably affected by limited sales volume available, start-up costs for new line, FX and record high electricity prices in quarter. Financial result in the quarter is according to plan and is expected to improve from Q2’22, with more volume available for sale.

The net profit ended at negative MNOK 15.2 (Q1’21: MNOK 8.8) for the first quarter of 2022.

At end of March both existing production line #1 and new line #2 was producing metformin. Line #1 producing according to plan. Line #2 producing at reduced capacity during initial ramp-up phase. Vistin has had significant start-up costs in the quarter driven by onboarding of new operators & quality FTE’s and semi-variable overhead costs, in addition to limited production. First commercial batch from the 2nd production line expected to be shipped out in Q2 ’22 as planned. Capacity is expected to ramp-up gradually during Q2-Q4 and reach an annual capacity of >5 500MT by end 2022. Annual capacity of approx. 7000MT expected to be reached during 2023.

Vistin Pharma had cash of MNOK 12 (Q1’21 MNOK: 85) as of 31 March 2022. Approx. 70% of the Metformin Expansion Project (MEP) has been paid as of end March and project cost is according to budget. The company has a strong balance sheet with an equity ratio of 82% and no interest-bearing debt.

The first quarter conference call, which will be held today, 27th of April, at 8.30am (CET) and will be available via web and audio through the following access points:

Telephone conference:
Confirmation Code:            8168697
International dial-In:         +44 (0) 2071 928338
Norway, Oslo:                   +47 21563015
United States, New York:   +1 6467413167

Webcast:
https://edge.media-server.com/mmc/p/s56tfz7e

The conference call will be held in English.    

Please find the Q1 report and presentation enclosed. The report will also be made available on www.vistin.com.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.